Project Grant R01AA033841
Award Date 9/1/26
Completion Date 6/30/31
Dollars Obligated $349K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Kansas City, KS 66160, USA
Similar Awards
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Kansas Medical Center Research Institute, Inc. $596,476 on May 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the role of acute phase response signaling in alcohol-associated liver disease resolution. The project, awarded as a Project Grant (R01AA032810), funds research examining how hepatocytes direct a resolution program following alcohol cessation, producing signals that alter liver...
- The National Institute on Alcohol Abuse and Alcoholism awarded the University of Kansas Medical Center Research Institute, Inc. $301,070 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate mechanisms that regulate hepatocyte fate during recovery from alcohol-associated hepatitis. The research addresses the pathogenesis of alcohol-associated liver disease, which progresses from simple steatosis to severe forms including alcoholic hepatitis, fibrosis,...
- The National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health within the Department of Health and Human Services, awarded $682,736 to Beth Israel Deaconess Medical Center, Inc. on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate myeloid-derived suppressor cells (MDSCs) in alcohol-associated steatohepatitis. The award funds research characterizing MDSC phenotypes and immunoregulatory capacity in alcohol-associated hepatitis...
- The National Institute on Alcohol Abuse and Alcoholism awarded The University of Texas Health Science Center at San Antonio $664,792 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate post-transcriptional mechanisms and cellular senescence in age-related alcoholic liver disease. The research targets dysregulated nutrient sensing as a hallmark of aging that drives hepatic steatosis progression toward cirrhosis and hepatocellular carcinoma. The recipient will...
- The National Institute on Alcohol Abuse and Alcoholism awarded Loyola University of Chicago Health Sciences Campus $470,066 on May 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to conduct basic research on the molecular mechanisms by which ABL kinase 2 (ABL2) contributes to alcohol-associated liver disease pathogenesis. The research will investigate three specific areas: the molecular mechanisms by which ABL2 promotes alcohol-induced steatosis; the role of ABL kinases in...
- The National Institute on Alcohol Abuse and Alcoholism awarded The Trustees of Columbia University in the City of New York $2,359,200 on July 15, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate the regulation of hepatocyte functions by hepatic stellate cells in steatotic liver diseases, including alcohol-associated liver disease, metabolic dysfunction-associated fatty liver disease, and mixed forms. The research characterizes an R-spondin 3-mediated hepatic stellate cell...
- The National Institute on Alcohol Abuse and Alcoholism awarded The University of Texas Southwestern Medical Center $478,080 on September 1, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate ferroptosis propagation in advanced alcoholic liver disease. The project, titled "Combating Advanced Alcoholic Liver Disease by Blocking Intercellular Signaling That Propagates Ferroptosis," addresses a cell death pathway triggered by lipid peroxide accumulation that spreads...
- The National Institute on Alcohol Abuse and Alcoholism (NIAAA), a division of the Department of Health and Human Services National Institutes of Health, awarded Yale University $663,419 on August 11, 2026, under the Alcohol Research Programs (CFDA 93.273) to investigate liver sinusoidal endothelial cell (LSEC) inflammation in alcohol-associated liver disease. The research addresses mechanisms by which alcohol disrupts LSEC homeostasis through two converging pathways: IL6 trans-signaling mediated...
- The National Institute on Alcohol Abuse and Alcoholism awarded Beth Israel Deaconess Medical Center, Inc. $2,072,751 under the Alcohol Research Programs (CFDA 93.273) on September 15, 2025. The recipient is conducting research into innate immune dysregulation in alcohol-associated liver disease, with focus on neutrophil heterogeneity and dysfunction in alcohol-associated hepatitis. The work characterizes transcriptomic profiles and functional roles of neutrophil populations—specifically...
- The National Institute on Alcohol Abuse and Alcoholism awarded Beth Israel Deaconess Medical Center, Inc. $177,736 on August 17, 2026, under the Alcohol Research Programs (CFDA 93.273) to support a postdoctoral researcher's career development in understanding the role of neutrophil extracellular traps (NETs) in alcohol-induced acute-on-chronic liver failure. The award funds a two-year mentored research program spanning August 17, 2026, through July 31, 2028, based in Boston, Massachusetts. The...